Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways
Anticancer Research · 2025
DOI: 10.21873/anticanres.17601 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Yui Suzuki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Molecular and Cellular Toxicology, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute o…. Hauptthemen laut MEDLINE: Vemurafenib, Melanoma, TOR Serine-Threonine Kinases, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Molecular and Cellular Toxicology, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, Saitama, Japan.
- Laboratory of Organic Synthesis and Medicinal Chemistry, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, Saitama, Japan.
- Unit of Molecular and Cellular Toxicology, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, Saitama, Japan; yajimai@shibaura-it.ac.jp.
Zitieren
APA
Suzuki, Y., Usuki, S., Nishizawa, M., Tanaka, N., Suhara, Y., & Yajima, I. (2025). Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways. Anticancer Research. https://doi.org/10.21873/anticanres.17601
Vancouver
Suzuki Y, Usuki S, Nishizawa M, Tanaka N, Suhara Y, Yajima I. Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways. Anticancer Research. 2025. doi:10.21873/anticanres.17601
BibTeX
@article{Suzuki2025,
author = {Suzuki, Yui and Usuki, Soichiro and Nishizawa, Mitsuaki and Tanaka, Noriyoshi and Suhara, Yoshitomo and Yajima, Ichiro},
title = {Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17601}
}
EUVIMED